Bone Therapeutics completed enrollment of 32 patients in the U.S. Phase IIA study of ALLOB® allogeneic bone-cell therapy in lumbar spinal fusion. Following 1-year follow-up, patient data is expected in mid-2019.
The trial is investigating the addition of ALLOB to use of an interbody cage with bone void filler, and will evaluate fusion, intervertebral mobility, function, pain reduction, etc.
As reported in late 3Q17, results from the first 15 patients showed evidence of successful spinal fusion and statistically significant improvements at 12 months.
Bone Therapeutics completed enrollment of 32 patients in the U.S. Phase IIA study of ALLOB® allogeneic bone-cell therapy in lumbar spinal fusion. Following 1-year follow-up, patient data is expected in mid-2019.
The trial is investigating the addition of ALLOB to use of an interbody cage with bone void filler, and will evaluate fusion,...
Bone Therapeutics completed enrollment of 32 patients in the U.S. Phase IIA study of ALLOB® allogeneic bone-cell therapy in lumbar spinal fusion. Following 1-year follow-up, patient data is expected in mid-2019.
The trial is investigating the addition of ALLOB to use of an interbody cage with bone void filler, and will evaluate fusion, intervertebral mobility, function, pain reduction, etc.
As reported in late 3Q17, results from the first 15 patients showed evidence of successful spinal fusion and statistically significant improvements at 12 months.
Copy to clipboard 
